HPV vaccination: The most pragmatic cervical cancer primary prevention strategy

International Journal of Gynecology and Obstetrics

Volumn 131, Issue , 2015, Pages S33-S35

  Sankaranarayanan, Rengaswamy ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Cervical cancer; HPV vaccination; National programs; Prevention; Screening

Indexed keywords

CANCER VACCINE; WART VIRUS VACCINE;

ARTICLE; CANCER PREVENTION; CANCER RISK; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; FEMALE; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; INCOME; INFECTION RISK; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PERSISTENT INFECTION; PRECANCER; PREVENTIVE HEALTH SERVICE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST; SOCIAL STATUS; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS; ALPHAPAPILLOMAVIRUS; DEVELOPING COUNTRY; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; PUBLIC HEALTH; STANDARDS; STATISTICS AND NUMERICAL DATA; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ALPHAPAPILLOMAVIRUS; DEVELOPING COUNTRIES; FEMALE; HUMANS; NATIONAL HEALTH PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84944034652     PISSN: 00207292     EISSN: 18793479     Source Type: Journal    
DOI: 10.1016/j.ijgo.2015.02.014     Document Type: Article

References (26)

1. J. Ferlay, I. Soerjomataram, M. Ervik, R. Dikshit, S. Eser, C. Mathers, and et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] 2013 IARC Lyon http://globocan.iarc.fr. Accessed October 29, 2014
2. A.B. Moscicki, M. Schiffman, A. Burchell, G. Albero, A.R. Giuliano, M.T. Goodman, and et al. Updating the natural history of human papillomavirus and anogenital cancers Vaccine 30 Suppl. 5 2012 F24 F33
3. International Agency for Research on Cancer IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Human Papillomavirus vol. 90 2007 IARC Lyon, France
4. A.G. Ostor Natural history of cervical intraepithelial neoplasia: a critical review Int J Gynecol Pathol 12 2 1993 186 192
5. M.R. McCredie, K.J. Sharples, C. Paul, J. Baranyai, G. Medley, R.W. Jones, and et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study Lancet Oncol 9 5 2008 425 434
6. R. Salani, I. Puri, and R.E. Bristow Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status Am J Obstet Gynecol 200 2 2009 182.e1 182.e5
7. K. Natunen, T.A. Lehtinen, S. Torvinen, and M. Lehtinen Cost-effectiveness of HPV-vaccination in medium or low income countries with high cervical incidence - A systematic review J Vaccines Vaccin 4 2013 172
8. M. Jit, M. Brisson, A. Portnoy, and R. Hutubessy Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study Lancet Glob Health 2 7 2014 e406 e414
9. J.T. Schiller, X. Castellsague, and S.M. Garland A review of clinical trials of human papillomavirus prophylactic vaccines Vaccine 30 Suppl. 5 2012 F123 F138
10. M. Diaz, J.J. Kim, G. Albero, S. de Sanjosé, G. Clifford, F.X. Bosch, and et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India Br J Cancer 99 2 2008 230 238
11. L.M. Reynales-Shigematsu, E.R. Rodrigues, and E. Lazcano-Ponce Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico Arch Med Res 40 6 2009 503 513
12. M. Fesenfeld, R. Hutubessy, and M. Jit Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review Vaccine 31 37 2013 3786 3804
13. I. Baussano, F. Lazzarato, G. Ronco, J. Dillner, and S. Franceschi Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries Int J Cancer 133 8 2013 1876 1881
14. E.H. Elbasha, E.J. Dasbach, and R.P. Insinga Model for assessing human papillomavirus vaccination strategies Emerg Infect Dis 13 1 2007 28 41
15. B. Romanowski, T.F. Schwarz, L.M. Ferguson, K. Peters, M. Dionne, K. Schulze, and et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study Hum Vaccin 7 12 2011 1374 1386
16. M. Safaeian, C. Porras, Y. Pan, A. Kreimer, J.T. Schiller, P. Gonzalez, and et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial Cancer Prev Res (Phila) 6 11 2013 1242 1250
17. S.R. Dobson, S. McNeil, M. Dionne, M. Dawar, G. Ogilvie, M. Krajden, and et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial JAMA 309 17 2013 1793 1802
18. B. Romanowski, T.F. Schwarz, L.M. Ferguson, M. Ferguson, K. Peters, M. Dionne, and et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study Hum Vaccin Immunother 10 5 2014 1155 1165
19. E. Lazcano-Ponce, M. Stanley, N. Munoz, L. Torres, A. Cruz-Valdez, J. Salmerón, and et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months Vaccine 32 6 2014 725 732
20. A.R. Kreimer, A.C. Rodriguez, A. Hildesheim, R. Herrero, C. Porras, M. Schiffman, and et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine J Natl Cancer Inst 103 19 2011 1444 1451
21. A. Binagwaho, F. Ngabo, C.M. Wagner, C. Mugeni, M. Gatera, C.T. Nutt, and et al. Integration of comprehensive women's health programmes into health systems: cervical cancer prevention, care and control in Rwanda Bull World Health Organ 91 9 2013 697 703
22. S.M. Garland The Australian experience with the human papillomavirus vaccine Clin Ther 36 1 2014 17 23
23. B. Baldur-Felskov, C. Dehlendorff, C. Munk, and S.K. Kjaer Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women J Natl Cancer Inst 106 3 2014 djt460
24. K. Kavanagh, K.G. Pollock, A. Potts, J. Love, K. Cuschieri, H. Cubie, and et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types Br J Cancer 110 11 2014 2804 2811
25. M.A. Smith, and K. Canfell Testing previous model predictions against new data on human papillomavirus vaccination program outcomes BMC Res Notes 7 2014 109
26. Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 - conclusions and recommendations Wkly Epidemiol Rec 89 21 2014 221 236